Pascal Gasser

Pascal Gasser

Auto-generated profile, based on publicly available information

Pascal Gasser

Mabylon AG Zürich Switzerland

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
PGPascal Gasser
Pascal Gasser
STSvetlana S. Tarchevskaya
Svetlana S. Tarchevskaya
PGPascal Guntern
Pascal Guntern
DBDaniel Brigger
Daniel Brigger
RRRahel Ruppli
Rahel Ruppli
AEAlexander Eggel
Alexander Eggel
Targeting of immunoglobulin E (IgE) represents an interesting approach for the treatment of allergic disorders. A high-affinity monoclonal anti-IgE antibody, ligelizumab, has recently been developed to overcome some of the limitations associated with the clinical use of the therapeutic anti-IgE antibody, omalizumab. Here, we determine the molecular binding profile and functional modes-of-action of ligelizumab. We solve the crystal structure of ligelizumab bound to IgE, and report epitope differences between ligelizumab and omalizumab that contribute to their qualitatively distinct IgE-receptor inhibition profiles. While ligelizumab shows superior inhibition of IgE binding to FcεRI, basophil activation, IgE production by B cells and passive systemic anaphylaxis in an in vivo mouse model, ligelizumab is less potent in inhibiting IgE:CD23 interactions than omalizumab. Our data thus provide a structural and mechanistic foundation for understanding the efficient suppression of FcεRI-dependent allergic reactions by ligelizumab in vitro as well as in vivo.

6 July 2020 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
DBDaniel Brigger
Daniel Brigger
CRCarsten Riether
Carsten Riether
RBRobin van Brummelen
Robin van Brummelen
KMKira I. Mosher
Kira I. Mosher
ASAlicia Shiu
Alicia Shiu
AEAlexander Eggel
Alexander Eggel

3 December 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
LPLuke F. Pennington
Luke F. Pennington
PGPascal Gasser
Pascal Gasser
SKSilke Kleinboelting
Silke Kleinboelting
CZChensong Zhang
Chensong Zhang
GSGeorgios Skiniotis
Georgios Skiniotis
TJTheodore S. Jardetzky
Theodore S. Jardetzky
Antibody drugs exert therapeutic effects via a range of mechanisms, including competitive inhibition, allosteric modulation, and immune effector mechanisms. Facilitated dissociation is an additional mechanism where antibody-mediated “disruption” of stable high-affinity macromolecular complexes can potentially enhance therapeutic efficacy. However, this mechanism is not well understood or utilized therapeutically. Here, we investigate and engineer the weak disruptive activity of an existing therapeutic antibody, omalizumab, which targets IgE antibodies to block the allergic response. We develop a yeast display approach to select for and engineer antibody disruptive efficiency and generate potent omalizumab variants that dissociate receptor-bound IgE. We determine a low resolution cryo-EM structure of a transient disruption intermediate containing the IgE-Fc, its partially dissociated receptor and an antibody inhibitor. Our results provide a conceptual framework for engineering disruptive inhibitors for other targets, insights into the failure in clinical trials of the previous high affinity omalizumab HAE variant and anti-IgE antibodies that safely and rapidly disarm allergic effector cells.

8 March 2024
Verified
Dataset
Open access
PLPennington Lf
Pennington Lf
GPGasser P
Gasser P
KSKleinboelting S
Kleinboelting S
ZCZhang C
Zhang C
SGSkiniotis G
Skiniotis G
JTJardetzky Ts
Jardetzky Ts
EMPIAR, the Electron Microscopy Public Image Archive centered at EMBL-EBI, is a public resource for raw electron microscopy images related to EMDB, contains micrographs, particle sets and tilt-series.

22 October 2026 in Clinical & Experimental Allergy
Verified
Journal Article
Open access
PDF file
PGPascal Gasser
Pascal Gasser
AOAlex A. J. Overman
Alex A. J. Overman
MPMojtaba Porbahaie
Mojtaba Porbahaie
CAChiara Arena
Chiara Arena
JKJuliane Konrad
Juliane Konrad
NWNatascha Wuillemin
Natascha Wuillemin
Background: Peanut allergy remains a clinical challenge, with limited treatment options such as omalizumab (Xolair) and allergen immunotherapy (AIT). However, these are constrained by eligibility and safety concerns. AIT induces protective allergen‐neutralizing IgG4 in most, but not all patients. Allergen‐neutralizing IgG4 competes with allergen‐specific IgE, inhibits FcεRI‐mediated mast cell activation, and inhibits IgE‐facilitated antigen presentation via CD23. Recent findings suggest that combining omalizumab with AIT enhances safety and reduces side effects. We hypothesize that controlled allergen exposure combined with peanut‐specific IgG4 mAbs (MY‐4‐mAbs) prevents IgE binding to peanut allergens, reduces CD23‐mediated allergen presentation and Th2 responses, and skews immunity towards protective allergen‐specific IgG while limiting allergen‐specific IgE induction. Methods: PBMCs from peanut‐allergic donors were exposed to Ara h 2 with or without MY‐4‐mAbs. Th2 cytokines, Foxp3+ Tregs, and IgE‐facilitated allergen binding (FAB) to B cells were assessed. In vivo, peanut‐sensitized C3H/HeJ mice underwent oral‐AIT with peanut extract with or without MY‐4‐mAbs and were monitored for anaphylaxis during and after oral‐AIT. Additionally, peanut‐specific IgG and IgE levels were measured before and after oral‐AIT. Results: Ex vivo, MY‐4‐mAbs with Ara h 2 suppressed Th2 cytokines, enhanced IL‐10 secretion, and inhibited FAB. MY‐4‐mAbs redirected allergen binding to myeloid antigen‐presenting cells and promoted tolerance‐associated responses. In vivo, the combination maintained peanut‐specific IgG induced during oral‐AIT, prevented increases in IgE, and reduced mast cell activation. Conclusions: Allergen‐specific IgG4 mAbs with controlled allergen exposure may improve the safety and efficacy of peanut AIT while promoting tolerance‐associated immune responses, which might allow disease modification towards allergen tolerance.